Sep 11, 2023 / 08:30PM GMT
Vernon Tolentino Bernardino - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good afternoon, everyone. Welcome to the H.C. Wainwright 25th Annual Global Investment Conference. I'm Vernon Bernardino, the senior analyst. I cover this tech company called Novavax, ticker NVAX, with a buy and a $35 price target. Some interesting news today, we'll get a chance to talk about it, but as you know, this is a company with a unique approach to the COVID-19 space, in that it's a standard approach, which is a protein-based technology.
With us today is the Chief Financial Officer, Jim Kelly. And a treat for me is Robert Walker, their Chief Medical Officer who's been onboarded in the past year. So earlier this year, with the change in management came some priorities that the company announced. One of them was to deliver of course an updated vaccine, another was to reduce the velocity of spend, management of cash and improve issues.
But also, again, something that has always been close to my heart, and that's this is a company that I've covered
Novavax Inc at HC Wainwright Investment Conference - New York Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers